{"filings":[{"id":861396,"accession_number":"0001600620-26-000053","cik":1600620,"company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","form_type":"8-K","filed_at":"2026-06-04T20:18:37+00:00","items":["5.07","9.01"],"status":"ready","headline":"Aurinia shareholders elect all five director nominees and approve auditor and say-on-pay at 2026 AGM","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Five directors elected: Kevin Tang (96.59%), Jeffrey Bailey (95.33%), Kathy Goetz (96.52%), Craig Johnson (86.50%), Tina S. Nova (86.89%).","PricewaterhouseCoopers LLP ratified as independent auditor with 89.14% votes for.","Say-on-pay advisory resolution approved with 93.10% for, 6.05% against, 0.85% abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1970177568.8236806,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":12,"accession_number":"0001140361-26-020402","cik":1600620,"company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","form_type":"8-K","filed_at":"2026-05-11T13:20:50+00:00","items":["2.01","9.01"],"status":"ready","headline":"Aurinia completes acquisition of Kezar Life Sciences for $6.955/share plus CVR","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Offer price: $6.955 cash per share plus one contingent value right (CVR).","5,927,580 shares tendered (~80.24% of outstanding) as of Expiration Time on May 8, 2026.","Merger completed on May 11, 2026 under DGCL Section 251(h); no stockholder vote required.","Outstanding in-the-money options converted to cash spread plus CVRs; out-of-the-money options cancelled.","CVR Agreement dated May 11, 2026 with Broadridge as Rights Agent and Fortis Advisors as Representative."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1970177568.8236806,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93992,"accession_number":"0001600620-26-000048","cik":1600620,"company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aurinia Q1 revenue $77.7M (+24% YoY), EPS $0.25 (+56%); reiterates FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales of LUPKYNIS were $73.6M, up 23% YoY.","Net income of $34.4M, up 48% YoY; diluted EPS $0.25 vs $0.16.","Cash from operations surged to $32.6M from $1.3M a year ago.","Repurchased 2.5M shares for $36.2M during Q1.","Reaffirms 2026 total revenue guidance of $315M–$325M and net product sales of $305M–$315M."],"consensus_eps_estimate":0.202,"consensus_eps_actual":0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":77705000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1970177568.8236806,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93991,"accession_number":"0001600620-26-000035","cik":1600620,"company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","form_type":"8-K","filed_at":"2026-04-03T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Aurinia to acquire Kezar for $6.955/share plus CVR; tender offer by April 13","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Aurinia (AUPH) to acquire Kezar (KZR) for $6.955 per share in cash plus one non-transferable CVR.","CVR entitles holders to potential payments from zetomipzomib milestones, Everest/Enodia proceeds, and Kezar's net cash over $50M.","Kezar's lead asset zetomipzomib is a first-in-class immunoproteasome inhibitor for autoimmune hepatitis and lupus.","Tang Capital Partners (9% holder) signed support agreement to tender shares; deal expected to close Q2 2026.","Kezar's board unanimously approved; TD Cowen and Cooley advised Kezar."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1970177568.8236806,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106031,"accession_number":"0001600620-26-000026","cik":1600620,"company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Aurinia appoints Chair Kevin Tang as CEO; entire C-suite replaced effective March 23, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kevin Tang (Chair) appointed CEO, succeeding Peter Greenleaf; Greenleaf to consult for 3 months at $600/hr.","Ryan Cole appointed COO ($300k salary, 50% bonus, 150k options); Michael Hearne appointed CFO (same terms).","Departures: Peter Greenleaf, Matthew Donley (COO), Gregory Keenan (CMO), Joseph Miller (CFO) effective March 20-21.","Thomas Wei appointed Chief Scientific Officer; Craig Johnson elected Lead Independent Director.","Kevin Tang will receive no salary, bonuses, or equity for his CEO role."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1970177568.8236806,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106030,"accession_number":"0001600620-26-000015","cik":1600620,"company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aurinia Q4 revenue up 29% to $77.1M, EPS $1.53; guides 2026 LUPKYNIS sales $305M-$315M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["LUPKYNIS net product sales for FY 2025: $271.3M, up 25% YoY; Q4 $74.2M, up 29%.","Net income for FY 2025: $287.2M ($2.07 diluted EPS) vs $5.8M ($0.04) in 2024; includes $173.0M tax benefit.","Cash, equivalents, restricted cash & investments: $398.0M at Dec 31, 2025; generated $135.7M from operations.","2026 guidance: total revenue $315M-$325M; LUPKYNIS net sales $305M-$315M (12-16% growth).","Initiated clinical study of aritinercept (BAFF/APRIL inhibitor); plan another autoimmune study in H1 2026."],"consensus_eps_estimate":0.221,"consensus_eps_actual":2.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":283055000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1970177568.8236806,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122324,"accession_number":"0001600620-25-000108","cik":1600620,"company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aurinia Q3 revenue $73.5M (+8%), net income $31.6M; LUPKYNIS sales up 27% YoY, FY guidance raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2025 net product sales of LUPKYNIS $70.6M, up 27% YoY; 9-month $197.2M, up 24%.","Diluted EPS $0.23 (Q3), up 130% YoY; net income $31.6M, up 119%.","FY 2025 net product sales guidance raised to $265-270M from $250-260M; total revenue guidance raised to $275-280M.","Cash from operating activities $44.5M in Q3, up 162% YoY; cash position $351.8M.","Positive Phase 1 results for aritinercept (BAFF/APRIL inhibitor); clinical studies in two autoimmune diseases planned by end of 2025."],"consensus_eps_estimate":0.1632,"consensus_eps_actual":0.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":205941000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1970177568.8236806,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139022,"accession_number":"0001600620-25-000090","cik":1600620,"company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Aurinia Q2 revenue up 22% to $70M; net income $21.5M; raises FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $70.0M (+22% YoY); net product sales $66.6M (+21%); net income $21.5M vs $0.7M in Q2 2024.","H1 2025 revenue $132.5M (+23%); net income $44.9M vs loss of $10.0M; operating cash flow $45.5M.","FY2025 total revenue guidance raised to $260-270M (from $250-260M); net product sales $250-260M.","Board approved $150M increase to share repurchase plan; $138.4M spent on 18.3M shares since Feb 2024.","Positive Phase 1 data for dual BAFF/APRIL inhibitor aritinercept; plans to start Phase 2 in 2H 2025."],"consensus_eps_estimate":0.1496,"consensus_eps_actual":0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":132473000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1970177568.8236806,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156533,"accession_number":"0001600620-25-000083","cik":1600620,"company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aurinia announces positive Phase 1 results for aritinercept; robust Ig reductions support once-monthly dosing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Single doses of aritinercept (5-300 mg s.c.) well tolerated in 61 healthy subjects; no treatment-related Grade ≥3 AEs or SAEs.","Mean immunoglobin reductions at Day 28: IgA up to 48%, IgM up to 55%, IgG up to 20%.","Injection site reactions in 24% aritinercept vs 13% placebo; all Grade 1.","Company plans to initiate clinical studies in at least two autoimmune diseases in H2 2025.","Pharmacodynamic effects support once-monthly subcutaneous dosing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1970177568.8236806,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156532,"accession_number":"0001600620-25-000057","cik":1600620,"company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"Aurinia shareholders approve amended equity plan, elect directors at 2025 AGM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amended Equity Incentive Plan (20,836,773 Plan Shares) at May 15, 2025 AGM.","All six director nominees elected: Kevin Tang, Jeffrey Bailey, Kathy Goetz, Peter Greenleaf, Craig Johnson, Tina Nova.","Shareholders ratified PwC as auditor (88.3M for, 5.5M against) and approved say-on-pay (58.9M for, 17.2M against).","Bylaw amendment effective May 15, 2025 gives shareholders right to set the number of directors.","Plan imposes minimum one-year vesting; up to 5% of Plan Shares may be granted with shorter vesting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1970177568.8236806,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156531,"accession_number":"0001600620-25-000047","cik":1600620,"company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aurinia Q1 revenue $62.5M (+24% YoY); net income $23.3M vs loss of $10.7M; LUPKYNIS sales up 25%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $62.5M, up 24% YoY; net product sales of LUPKYNIS were $60.0M (+25% YoY).","Net income $23.3M vs net loss $(10.7)M in Q1 2024; cash flow from operations $1.3M ($12.4M ex-restructuring).","Cash and investments $312.9M; repurchased 5.8M shares for $47.4M in Q1.","Full-year 2025 revenue guidance reaffirmed: $250-$260M; net product sales guidance $240-$250M.","Initial Phase 1 results for dual BAFF/APRIL inhibitor AUR200 expected later this quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":62465000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1970177568.8236806,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174956,"accession_number":"0001600620-25-000009","cik":1600620,"company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aurinia Q4 2024 net income $1.4M on 33% revenue growth, LUPKYNIS sales up 36% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $59.9M (+33% YoY); net product sales $57.6M (+36%); license revenue $2.3M (-18%).","Q4 net income $1.4M vs $(26.9)M loss; full year net income $5.8M vs $(78.0)M loss.","Cash flow from operations Q4 $30.1M (+110% YoY); full year $44.4M vs $(33.5)M.","2025 guidance: total revenue $250-260M, net product sales $240-250M; AUR200 Phase 1 data expected Q2 2025.","Cash $358.5M at Dec 31, 2024; repurchased 6.1M shares for $41M in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":235133000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1970177568.8236806,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191917,"accession_number":"0001600620-24-000106","cik":1600620,"company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","2.05","5.02","9.01"],"status":"ready","headline":"Aurinia Q3 net product rev $55.5M (+36% YoY), net income $14.4M; restructuring cuts 45% workforce","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q3 total net revenue $67.8M; net product revenue $55.5M (+36% YoY); net income $14.4M vs loss of $13.4M a year ago.","Strategic restructuring: workforce reduction ~45%, expects annual cash savings >$40M, one-time Q4 charge $15-19M.","FY2024 net product revenue guidance reiterated $210-220M; YTD net product revenue $158.6M.","AUR200 Phase 1 first participant dosed; initial results expected H1 2025.","Board: Craig Johnson appointed, Dr. Robert Foster retired (not due to disagreement)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1970177568.8236806,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208376,"accession_number":"0001600620-24-000099","cik":1600620,"company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","form_type":"8-K","filed_at":"2024-09-12T23:59:59+00:00","items":["5.02","7.01","5.03","9.01"],"status":"ready","headline":"Aurinia restructures board: 3 directors resign, Kevin Tang appointed, CEO Greenleaf stays","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board accepted conditional resignations of Daniel Billen, Hector MacKay-Dunn, and Brinda Balakrishnan, effective Sept 9, 2024.","CEO Peter Greenleaf remains director; Board cited exceptional circumstances for rejecting his conditional resignation.","Kevin Tang, President of Tang Capital Management, appointed as director effective Sept 12, 2024.","Board reduced from 9 to 7 members; Amended and Restated Bylaws now authorize Board to set director count."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1970177568.8236806,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208375,"accession_number":"0001600620-24-000089","cik":1600620,"company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aurinia Q2 net product revenue $55M (+34% YoY); net income $0.7M, cash flow positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue $55.0M, up 34% YoY; total net revenue $57.2M (+38% YoY).","Net income $0.7M vs loss of $11.5M in Q2 2023; generated $15.8M free cash flow.","Narrows 2024 net product revenue guidance to $210-220M from $200-220M.","2,336 patients on LUPKYNIS (+22% YoY); AUR200 Phase 1 SAD starts Q3 2024.","Cash $330.7M; repurchased 3.4M shares for $18.6M YTD."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":107495000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1970177568.8236806,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226046,"accession_number":"0001600620-24-000087","cik":1600620,"company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Aurinia shareholders reject say-on-pay, equity plan; four directors face conditional resignations","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Peter Greenleaf and three other directors received less than majority support; conditional resignations submitted under Majority Voting Policy.","Say-on-pay vote failed: 30.8M for, 45.3M against, 0.5M abstain.","Equity Incentive Plan amendment not approved: 35.7M for, 40.5M against.","PricewaterhouseCoopers ratified as auditor with 85.6M for, 8.1M against.","Board will decide on the four directors' resignations within 90 days per policy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.15,"market_cap_usd":1970177568.8236806,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226045,"accession_number":"0001600620-24-000049","cik":1600620,"company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aurinia Q1 net product revenue $48.1M (+40% YoY); expects Q2 cash flow positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net revenue $50.3M (+46% YoY); net loss narrowed to $10.7M ($0.07/sh) from $26.2M.","Restructuring completed with $50-55M annual cost savings; headcount reduced ~25%.","Company expects to be cash flow positive (ex buybacks) in Q2 2024, ahead of prior guidance.","Reaffirms FY2024 net product revenue guidance of $200-220M.","FDA approved label update for LUPKYNIS removing one-year efficacy limitation; quarterly kidney assessment after year one."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":50303000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1970177568.8236806,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245130,"accession_number":"0001600620-24-000027","cik":1600620,"company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Aurinia terminates EVP R&D Volker Knappertz in restructuring","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Volker Knappertz, EVP R&D, to be terminated as part of Aurinia's Feb 15 restructuring.","Severance includes 12 months base salary, accrued vacation, performance bonus payout.","Eligible for medical, dental, vision benefits for up to 12 months if release is provided.","Employment agreement terms filed as Exhibit 10.18 to 2023 10-K on Feb 15, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1970177568.8236806,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245129,"accession_number":"0001600620-24-000010","cik":1600620,"company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","form_type":"8-K","filed_at":"2024-02-15T23:59:59+00:00","items":["2.02","2.05","8.01","9.01"],"status":"ready","headline":"Aurinia reports 2023 net product revenue up 53% to $158.5M; ends strategic review, initiates $150M buyback","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net product revenue $158.5M (+53% YoY); net loss $78.0M ($0.54/shr) vs $108.2M loss in 2022.","Discontinues AUR200/AUR300 development; expects $11-15M Q1'24 charge and $50-55M annual savings; headcount cut ≥25% (non-commercial).","Board authorizes up to $150M share repurchase; max subject to Canadian regulatory approval; purchases start Feb 21, 2024.","Strategic review concluded after engaging 60+ parties; one non-binding expression of interest did not lead to formal offer.","Reaffirms 2024 net product revenue guidance of $200-220M; 2,066 patients on LUPKYNIS at year-end (vs 1,525)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1970177568.8236806,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245128,"accession_number":"0001600620-24-000001","cik":1600620,"company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","form_type":"8-K","filed_at":"2024-01-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aurinia preliminary Q4 net product revenue $42M (+49% YoY); FY23 $159M; guides FY24 $200-220M","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Preliminary net product revenue Q4 2023: ~$42M, up 49% YoY from $28.3M; full-year ~$159M, up 53% from $103.5M.","Total revenue Q4: ~$45M (+59% YoY); full-year ~$176M (+31% YoY); cash & investments ~$351M at year-end.","Guides 2024 net product revenue $200-220M; targets cash flow positive in H2 2024.","Patients on LUPKYNIS therapy: ~2,066 at Dec 31, 2023, up from 1,525 a year earlier; 438 PSFs added in Q4.","Strategic review process ongoing; no further updates on potential sale or merger at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":175513000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1970177568.8236806,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262564,"accession_number":"0001600620-23-000043","cik":1600620,"company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aurinia Q3 net product revenue $40.8M (+60% YoY); narrows FY2023 guidance to $155-160M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue $40.8M in Q3, up 60% YoY; 9-month net product revenue $116.2M (+55%).","Narrowed FY2023 net product revenue guidance to $155-160M from prior range.","Net loss $13.4M ($0.09/share) vs $9.0M ($0.06/share) in Q3 2022; 9-month net loss improved to $51.1M from $82.1M.","Patients on LUPKYNIS at Sept 30: ~1,939 (+43% YoY); 436 PSFs added in Q3 (+17%).","Received $10M milestone from Otsuka for European pricing and reimbursement in three major markets."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":130418000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1970177568.8236806,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279773,"accession_number":"0001600620-23-000040","cik":1600620,"company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","form_type":"8-K","filed_at":"2023-09-21T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"Aurinia appoints founder Dr. Foster to board; enters cooperation agreement with MKT Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dr. Robert T. Foster appointed to Board effective Sept 21, 2023; term expires at 2024 Annual Meeting.","MKT Capital agrees to standstill until Oct 31, 2024 (with conditions) and 7% ownership cap.","Dr. Foster receives standard non-employee director compensation: $45K annual cash, $200K annual equity, $340K new director grant.","Dr. Foster retains 2% royalty on voclosporin licensee sales and 0.3% of direct net sales ($307,254 in FY2022).","Press release notes Dr. Foster discovered voclosporin; strategic review remains ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1970177568.8236806,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279772,"accession_number":"0001600620-23-000030","cik":1600620,"company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","form_type":"8-K","filed_at":"2023-08-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Aurinia appoints Dr. Karen Smith and Jeffrey A. Bailey to Board; Dr. Daniel G. Billen named Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Karen Smith and Jeffrey A. Bailey joined Aurinia's Board effective August 18, 2023, bringing decades of biopharma leadership experience.","Dr. Daniel G. Billen, board member since 2019, appointed Chair of the Board of Directors.","Both new directors have experience with successful sales, mergers, and partnerships, relevant to the ongoing strategic review process.","Dr. Smith has served on boards of several acquired companies (Forward Pharma, Sucampo, Acceleron, Antares Pharma).","Mr. Bailey has held CEO and Chairman roles, including Chairman of Tekla Capital Management since 2020."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1970177568.8236806,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279771,"accession_number":"0001600620-23-000028","cik":1600620,"company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aurinia Q2 revenue up 47% to $41.5M; raises FY 2023 guidance to $150-160M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net revenue $41.5M (+47% YoY); net loss narrowed to $11.5M ($0.08 loss per share) from $35.5M ($0.25).","Raised FY2023 LUPKYNIS revenue guidance to $150-160M; cited strong commercial execution.","Patients on therapy reached 1,911 (+50% YoY); patient start forms +10% YoY to 451 in Q2.","Gross margin 96%; cash and short-term investments $350.7M as of June 30, 2023.","Initiated strategic review with J.P. Morgan as financial advisor."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":75903000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1970177568.8236806,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279770,"accession_number":"0001600620-23-000027","cik":1600620,"company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","form_type":"8-K","filed_at":"2023-07-03T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Aurinia board explores strategic alternatives including sale; two directors resign after vote shortfall","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board initiated exploration of strategic alternatives including sale, merger, or other transaction.","Retained JP Morgan as financial advisor; Skadden Arps and Borden Ladner Gervais as legal counsel.","Directors George Milne and Joseph Hagan resigned effective June 29 after less-than-majority support at AGM.","Korn Ferry engaged to search for two new board members.","No timetable set; no assurance of any transaction outcome."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1970177568.8236806,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298215,"accession_number":"0001600620-23-000015","cik":1600620,"company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","form_type":"8-K","filed_at":"2023-05-17T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Aurinia shareholders reject say-on-pay, equity plan; two directors resign after low support","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Directors Milne and Hagan received less than majority support; resignations submitted per Majority Voting Policy; board to decide.","Non-binding say-on-pay failed: 26.85M for, 42.75M against, plus 20.02M broker non-votes.","Equity Incentive Plan amendment not approved: 30.71M for, 39.15M against, plus 20.02M broker non-votes.","PricewaterhouseCoopers appointed auditor with 79.86M for, 6.86M against.","All eight director nominees elected but Milne and Hagan had lower support; others had 40-44M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.15,"market_cap_usd":1970177568.8236806,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298214,"accession_number":"0001600620-23-000010","cik":1600620,"company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aurinia Q1 net revenue $34.4M (+59% YoY); raises 2023 revenue guidance to $135-155M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue $34.3M, up from $21.5M in Q1 2022; net loss $26.2M ($0.18/share) vs $37.6M loss a year ago.","Raised FY 2023 LUPKYNIS net product revenue guidance to $135-155M, from prior $120-140M.","1,731 patients on LUPKYNIS therapy at March 31, 2023, up from 1,071 a year earlier; 466 PSFs added in Q1.","New method-of-use patent issued; NICE positive recommendation for LUPKYNIS in UK; Swiss regulatory approval received.","Cash and short-term investments $361.5M at quarter end vs $389.4M at Dec 31, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":34409000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1970177568.8236806,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298213,"accession_number":"0001600620-23-000004","cik":1600620,"company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","form_type":"8-K","filed_at":"2023-04-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aurinia reports positive renal biopsy data for LUPKYNIS in lupus nephritis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Repeat biopsies from 16 voclosporin and 10 control patients over 18 months.","Activity scores improved similarly in both arms; chronicity scores stable.","Data differentiates LUPKYNIS from first-generation CNIs on nephrotoxicity.","Further data to be presented at Congress of Clinical Rheumatology May 4-7, 2023.","Conference call/webcast at 8:30 am EDT on April 5, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1970177568.8236806,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318462,"accession_number":"0001628280-23-007613","cik":1600620,"company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Aurinia confirms no deposits or accounts at Silicon Valley Bank","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Aurinia states it does not hold any deposits, securities, or maintain any accounts at SVB.","Disclosure made on March 13, 2023, during the SVB collapse, reassuring investors of no exposure.","No financial impact from SVB failure as Aurinia has no direct or indirect exposure to the bank."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1970177568.8236806,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318461,"accession_number":"0001628280-23-005333","cik":1600620,"company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","form_type":"8-K","filed_at":"2023-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aurinia Q4 2022 net revenue $28.4M (+21% YoY); FY net revenue $134.0M (+194% YoY); net loss $0.18/share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 net product revenue $28.3M; FY 2022 net product revenue $103.5M.","Net loss Q4 $26.0M ($0.18/share); FY net loss $108.2M ($0.76/share).","Cash, equivalents and investments $389.4M at Dec 31, 2022.","FY 2023 net product revenue guidance reiterated at $120-140M.","Approx. 1,525 patients on LUPKYNIS therapy at year-end; 274 PSFs secured through Feb 24, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":134030000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1970177568.8236806,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318460,"accession_number":"0001628280-23-001666","cik":1600620,"company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","form_type":"8-K","filed_at":"2023-01-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Aurinia receives key patent allowance for LUPKYNIS dosing and PTAB terminates IPR challenge","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["USPTO allowed patent application 17/713,140 for LUPKYNIS dosing with eGFR, extending protection to 2037.","PTAB terminated Inter Partes Review of Aurinia's U.S. Patent No. 10,286,036 (Orange Book-listed).","New patent supplements existing method-of-use patent; Aurinia intends to list it in Orange Book when issued."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1970177568.8236806,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318459,"accession_number":"0001628280-23-000762","cik":1600620,"company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aurinia reports preliminary Q4 net revenue $28.4M; LUPKYNIS patients up to 1,525","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Preliminary Q4 2022 net revenue ~$28.4M, full-year net revenue ~$134.0M.","Net product revenue Q4 ~$28.3M, full-year ~$103.5M; 2022 guidance achieved.","LUPKYNIS patients on therapy at Dec 31, 2022: 1,525, up from 1,354 at Sep 30, 2022.","Q4 patient start forms ~406, compared to 374 in Q3 2022.","Reiterates 2023 net product revenue guidance of $120-140M; cash & investments ~$388.7M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":134030000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1970177568.8236806,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318458,"accession_number":"0001628280-23-000097","cik":1600620,"company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","form_type":"8-K","filed_at":"2023-01-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Aurinia settles patent dispute with Sun Pharma, ends IPR and litigation","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Joint motion to terminate IPR on Aurinia's U.S. Patent No. 10,286,036 filed.","Parties agree to dismiss all claims and counterclaims in patent litigation over Sun's CEQUA product.","Settlement conditional on USPTO approval of IPR termination.","No financial terms disclosed; both parties cease future actions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1970177568.8236806,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336717,"accession_number":"0001628280-22-027930","cik":1600620,"company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aurinia Q3 net revenue $55.8M (incl. $30M milestone); lowers FY22 product revenue guidance to $100-105M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss narrowed to $9.0M ($0.06/sh) from $50.3M loss ($0.39/sh) in Q3 2021.","LUPKYNIS net product revenue $25.5M; 2022 product revenue guidance cut to $100-105M from unstated prior range.","Patients on therapy grew to ~1,354 (up from 1,274 at Q2 2022); PSFs added 374 vs 412 Y/Y.","EC granted marketing authorization for LUPKYNIS in Europe; $30M milestone from Otsuka recognized and received.","Cash at $376.6M (Sep 30) and ~$400M (Oct 31); IPR decision on LUPKYNIS patent expected by July 26, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":105595000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1970177568.8236806,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336716,"accession_number":"0001628280-22-026779","cik":1600620,"company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","form_type":"8-K","filed_at":"2022-10-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Aurinia EVP Research and CMO depart effective Oct 31, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert Huizinga, EVP Research, and Neil Solomons, CMO, mutually agreed to leave Aurinia.","Huizinga severance: $575,015 base pay, $159,311 vacation, $191,672 bonus target (50% of 2022).","Solomons severance: $698,230 base pay, $192,157 vacation, $232,743 bonus target (50% of 2022).","Both departures effective Oct 31, 2022; benefits coverage for up to 18 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1970177568.8236806,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354105,"accession_number":"0001628280-22-025148","cik":1600620,"company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","form_type":"8-K","filed_at":"2022-09-19T23:59:59+00:00","items":["7.01","5.02","9.01"],"status":"ready","headline":"Aurinia receives EU marketing authorization for LUPKYNIS; director Walbert resigns","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["EC grants marketing authorization for LUPKYNIS (voclosporin) to treat active lupus nephritis in EU, Iceland, Liechtenstein, Norway, and Northern Ireland.","Aurinia to receive $30M milestone payment from Otsuka for EC approval; cash within 30 days of invoicing.","Director Timothy P. Walbert resigns from Board effective Sept. 19, 2022; no disagreement with company.","LUPKYNIS previously received FDA approval in Jan. 2021 for same indication."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1970177568.8236806,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354104,"accession_number":"0001628280-22-020811","cik":1600620,"company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aurinia Q2 2022 revenue up to $28.2M; net loss narrows to $0.25/share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net product revenue $28.2M vs $6.6M YoY; six month revenue $49.8M.","Net loss $35.5M ($0.25/share) vs $47.0M ($0.37) in Q2 2021.","LUPKYNIS patients on treatment ~1,274 at June 30, up 19% from Q1 2022.","2022 net revenue guidance reaffirmed at $115-$135M.","Positive CHMP opinion in Europe; EC decision expected by end of Q3 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":49816000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1970177568.8236806,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354103,"accession_number":"0001628280-22-018937","cik":1600620,"company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","form_type":"8-K","filed_at":"2022-07-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Aurinia and CCO Max Colao mutually agree to separation effective July 22","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Max Colao, Chief Commercial Officer, will cease employment on July 22, 2022 by mutual agreement.","Severance includes 12 months base salary ($488,835) plus eligibility for performance bonus (target $244,418).","COBRA benefits for up to 12 months if elected.","No replacement named; separation agreement expected to mirror existing employment terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1970177568.8236806,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371982,"accession_number":"0001628280-22-015026","cik":1600620,"company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","form_type":"8-K","filed_at":"2022-05-20T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Aurinia shareholders elect all nine board nominees and approve auditor and say-on-pay at 2022 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All nine director nominees elected; for votes ranged from 24.1M (Hagan) to 34.3M (Balakrishnan); broker non-votes 27.9M.","PricewaterhouseCoopers ratified as independent auditor: 63.3M for, 6.7M against, 2.0M abstain.","Say-on-pay advisory resolution approved: 33.1M for, 10.5M against, 0.6M abstain; 27.9M broker non-votes.","Meeting held virtually on May 17, 2022; results reported on May 20, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":1970177568.8236806,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371981,"accession_number":"0001628280-22-013437","cik":1600620,"company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","form_type":"8-K","filed_at":"2022-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aurinia Q1 net revenue $21.6M, net loss $37.6M; FY22 guidance reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue $21.6M (Q1 2021: $0.9M); net loss $37.6M ($0.27/shr) vs $50.4M ($0.40) YoY.","Maintains FY2022 LUPKYNIS revenue guidance $115-$135M, representing 150-200% growth over FY2021.","Patients on LUPKYNIS reached ~1,071 at March 31, 2022, up 21% from 884 at December 31, 2021.","EMA review on track; European Commission decision expected in second half of 2022.","Cash, cash equivalents and investments $418.8M at March 31, 2022, down from $466.1M at year-end 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":21625000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1970177568.8236806,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390891,"accession_number":"0001628280-22-004080","cik":1600620,"company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","form_type":"8-K","filed_at":"2022-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aurinia Q4 net revenue $23.4M, FY loss $181M; FY22 LUPKYNIS guidance $115-135M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2021 net revenue $23.4M (60% increase from Q3); full year net revenue $45.6M.","Net loss Q4 $33.3M ($0.25/share) vs $8.1M ($0.06) in Q4 2020; full year $181M ($1.40/share).","FY 2022 LUPKYNIS net revenue guidance $115-135M, representing 150-200% YoY growth.","Cash, equivalents & investments $466.1M at Dec 31, 2021; raised $196.7M net via ATM at avg $19.91.","AURORA 2 continuation study shows sustained efficacy; EMA MAA on track for CHMP opinion H2 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":45605000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1970177568.8236806,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390890,"accession_number":"0001628280-22-000527","cik":1600620,"company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","form_type":"8-K/A","filed_at":"2022-01-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aurinia reports positive 3-year AURORA 2 data for LUPKYNIS; no new safety signals","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["eGFR stable over 36 months; +2.7 mL/min vs control from baseline.","Serious AE rates: 19% voclosporin vs 24% control; 0 deaths in voclosporin arm vs 4 in placebo.","Mean UPCR lower in voclosporin group at all time points over 3 years.","Withdrawal rate: 12.9% voclosporin vs 15.0% control; drug well tolerated.","AURORA 2 enrolled 216 LN patients; 90 voclosporin and 78 control completed 36 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1970177568.8236806,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":409002,"accession_number":"0001628280-21-024728","cik":1600620,"company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","form_type":"8-K","filed_at":"2021-12-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aurinia reports positive long-term safety data from AURORA 2 study of LUPKYNIS in lupus nephritis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["116 voclosporin-treated patients showed stable mean eGFR over 36 months; +2.7 mL/min increase from baseline vs control.","Serious adverse event rates lower in voclosporin group (19% vs 24% control); no deaths vs 4 in control.","Mean UPCR lower in voclosporin group at all time points over three years.","Withdrawal rate lower in voclosporin group (12.9% vs 15.0% control); drug well tolerated overall."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1970177568.8236806,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":409001,"accession_number":"0001628280-21-021239","cik":1600620,"company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","form_type":"8-K","filed_at":"2021-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aurinia Q3 revenue $14.7M (+122% QoQ); net loss $50.3M; LUPKYNIS PSF conversion >68%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $14.7M vs $29K in Q3 2020; net loss $50.3M ($0.39 per share) vs $42.1M loss a year ago.","Cash and investments $286.4M; 2021 revenue guidance maintained at $40-50M.","LUPKYNIS PSFs totaled 412 in Q3; cumulative >1,265; conversion rate improved to >68% from 50% in Q2.","Payer coverage confirmed for 87% of total lives; two preclinical assets AUR200 and AUR300 added.","AURORA 2 final results expected by end of 2021; Swiss MAA filed; EMA decision anticipated Q3 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":22201000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1970177568.8236806,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":427924,"accession_number":"0001628280-21-018843","cik":1600620,"company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","form_type":"8-K/A","filed_at":"2021-09-17T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Aurinia board adopts annual say-on-pay votes following shareholder advisory vote","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board determined to hold annual say-on-pay votes after 56,605,305 shares (approx. 92% of votes cast) favored a 1-year frequency.","Only 956,039 shares voted for 2 years and 2,443,425 for 3 years; 1,841,663 abstained; 31,597,699 broker non-votes.","Decision aligns with board's recommendation in proxy statement for the 2021 Annual Meeting.","Annual say-on-pay will continue until the next required advisory vote on frequency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":1970177568.8236806,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":427927,"accession_number":"0001628280-21-017175","cik":1600620,"company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","form_type":"8-K","filed_at":"2021-08-17T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Aurinia licenses novel peptide AUR300 from Riptide for autoimmune/fibrotic diseases; $6M upfront","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Global licensing/research pact with Riptide for peptide AUR300 targeting M2 macrophages via CD206 receptor.","Aurinia pays $6M upfront; potential milestones and royalties on future sales of AUR300.","AUR300 reduces M2 dysregulation and inflammatory cytokines, aiming to treat autoimmune and fibrotic diseases.","Joint development committee formed; Riptide handles tech transfer and indication research activities.","Deal expands Aurinia's pipeline beyond LUPKYNIS into fibrosis and other autoimmune conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1970177568.8236806,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":427926,"accession_number":"0001628280-21-015854","cik":1600620,"company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","form_type":"8-K","filed_at":"2021-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aurinia Q2 2021 revenue $6.6M, 415 LUPKYNIS PSFs, guides FY revenue $40-50M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $6.6M (624% growth over Q1 2021); net loss $47.0M ($0.37/share) vs $26.5M loss in Q2 2020.","Received 415 LUPKYNIS patient start forms in Q2, over 800 YTD; >50% converted to therapy.","Cash and investments $323.7M; 2021 LUPKYNIS net revenue guidance $40-50M.","Otsuka filed MAA in EU for voclosporin; Aurinia eligible for up to $30M milestones plus royalties.","Appointed Dr. Brinda Balakrishnan to Board; Lancet published AURORA-1 results."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":7534000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1970177568.8236806,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":427925,"accession_number":"0001628280-21-013970","cik":1600620,"company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","form_type":"8-K","filed_at":"2021-07-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aurinia voluntarily delists from TSX effective July 30, 2021; continues on Nasdaq","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Delisting from Toronto Stock Exchange effective July 30, 2021; no shareholder approval required.","Nasdaq accounted for ~94% of daily trading volume over past 12 months.","Dual listing costs and administrative burden no longer justified given low TSX volume.","Common shares continue trading on Nasdaq under ticker AUPH.","Canadian brokers can trade Nasdaq-listed shares; shareholder value unaffected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1970177568.8236806,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}